TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
DUBLIN - Investment firm Citadel Group has disclosed a 1.17% stake in Mural Oncology plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds 202,953 shares representing 1.17% of Mural Oncology, alongside a short position of 0.75% as of August 11.
The filing details Citadel’s position includes 164,853 owned or controlled shares, representing 0.95% of the company, plus additional exposure through stock-settled derivatives including options.
The disclosure also documents multiple transactions conducted on August 11, with Citadel both buying and selling Mural Oncology shares at prices ranging from $1.55 to $1.64 per share. The largest single purchase was 5,000 shares at $1.60 per unit.
Additionally, Citadel reported options transactions, including the purchase of call options for 11,400 shares at a $2.50 strike price expiring January 2027, and put options for 30,000 shares at the same strike price and expiration date.
Irish takeover rules require public disclosure when an entity’s interest in a company reaches or exceeds 1% during an offer period.
The information was provided in a Form 8.3 filing, which is required for opening position disclosures under Irish Takeover Panel regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.